+164.3%
EWY vs GSK
+31.2%
+133.0%
-34.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.6% | -1.9% | +6.5% | +4.5% |
| 7D | +4.8% | -1.8% | +6.6% | +4.7% |
| 30D | +11.7% | -2.2% | +13.8% | +11.6% |
| 3M | -7.4% | -1.8% | -5.6% | -7.7% |
| 6M | +40.6% | -10.6% | +51.2% | +42.7% |
| YTD | +94.3% | +4.4% | +89.8% | +96.2% |
| 1Y | +164.3% | +30.4% | +133.9% | +164.7% |
| All | +164.3% | +31.2% | +133.0% | +164.7% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling